Skip to main content

Table 2 Clinical and virological relapses after cessation of nucleos(t)ide analogues in patients with negative HBeAg and undetectable viral DNA at the end of treatment

From: Time-varying serum gradient of hepatitis B surface antigen predicts risk of relapses after off-NA therapy

All (N = 140)
  First year Second year
Virological relapse 62.0% (95% CI, 53.5–70.6%) 79.2% (95% CI, 70.9–86.4%)
Clinical relapse 28.4% (95% CI, 21.2–37.5%) 42.9% (95% CI, 34.1–52.8%)